Abstract
Given the poor outcome of relapsed and refractory peripheral T cell lymphoma (PTCL), we explored a combination of lenalidomide, vorinostat, and dexamethasone to test the feasibility of this therapy in relapsed and refractory PTCL. Eight patients were accrued: two peripheral T cell lymphoma, unspecified; five angioimmunoblastic T cell lymphoma; and one ALK-negative anaplastic large-cell lymphoma. A dose escalation of lenalidomide (days 1–21, q28) was planned using a 3 + 3 design. As two patients treated with 10 mg/day experienced dose-limiting toxicity (thrombocytopenia grade 3, stroke grade 4), the primary end point of our trial was reached; the maximal tolerable dose of lenalidomide was 5 mg/day (level -I). Adverse events grade ≥3 were observed as thrombocytopenia (23 %), leukocytopenia (15 %), anemia (8 %), and neutropenia (8 %). One complete remission (10.3 months), one partial remission (11.3 months), one stable disease (11.9 months), and four progressive disease (overall response rate 25 %) were observed. The median progression-free survival was 2.2 months and the median OS was 6.7 months. In conclusion, the poor results obtained with lenalidomide in combination with vorinostat and dexamethasone provide no arguments that could justify further investigation of this drug combination for the treatment of relapsed PTCL.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, Villa D, Gascoyne RD, Connors JM, Savage KJ (2013) Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol Off J Am Soc Clin Oncol. doi:10.1200/jco.2012.44.7524
Coiffier B, Brousse N, Peuchmaur M, Berger F, Gisselbrecht C, Bryon PA, Diebold J (1990) Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d’Etude des Lymphomes Agressives). Ann Oncol Off J Eur Soc Med Oncol/ESMO 1(1):45–50
Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES, Ling A, Turner M, Peer CJ, Figg WD, Steinberg SM, Smith S, Joske D, Lewis I, Hutchins L, Craig M, Fojo AT, Wright JJ, Bates SE (2011) Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 117(22):5827–5834. doi:10.1182/blood-2010-10-312603
Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109(1):31–39. doi:10.1182/blood-2006-06-025999
Beckers MM, Huls G (2013) Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide. Eur J Haematol 90(2):162–163. doi:10.1111/ejh.12053
Dueck G, Chua N, Prasad A, Finch D, Stewart D, White D, van der Jagt R, Johnston J, Belch A, Reiman T (2010) Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 116(19):4541–4548. doi:10.1002/cncr.25377
Zinzani PL, Pellegrini C, Broccoli A, Stefoni V, Gandolfi L, Quirini F, Argnani L, Berti E, Derenzini E, Pileri S, Baccarani M (2011) Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. Leuk Lymphoma 52(8):1585–1588. doi:10.3109/10428194.2011.573031
Swerdlow SH; Campo E; HN, et al.eds. (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC
Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, Glaisner S, Gabarre J, Bosly A, Lister J, Li J, Coiffier B (2013) A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid(R)) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer (Oxford, England : 1990). doi:10.1016/j.ejca.2013.04.029
Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M (2007) Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol: Off J Am Soc Clin Oncol 25(21):3109–3115. doi:10.1200/jco.2006.10.2434
Uike N, Ogura M, Imaizumi Y, Asou N, Utsunomiya A, Uchida T, Aoki T, Tsukasaki K, Taguchi J, Choi I, Maruyama D, Nosaka K, Chen N, Shiota T, Tobinai K (2012) Multicenter phase I dose-escalation study of lenalidomide in patients with relapsed adult T-cell leukemia-lymphoma (ATL) or peripheral t-cell lymphoma (PTCL). ASH Annu Meet Abstr 120(21):2737
Hofmeister CC, Bowers MA, Efebera YA, Humphries K, Benson DM Jr, Greenfield CN, Sell M, Devine SM (2012) Phase I trial of lenalidomide + vorinostat after autologous transplant in multiple myeloma. ASH Ann Meet Abstr 120(21):3114
Richter JR, Bilotti E, McBride L, Schmidt L, Gao Z, Tufail M, Anand P, McNeill A, Bednarz U, Graef T, Vesole DH, Siegel DS (2011) Salvage therapy with vorinostat, lenalidomide, and dexamethasone (ZRD) in lenalidomide/dexamethasone relapsed/refractory multiple myeloma. ASH Ann Meet Abstr 118(21):3986
Conflict of interest
G.H. received financial support and lenalidomide from Celgene to conduct the study. The remaining authors declare no competing financial interests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hopfinger, G., Nösslinger, T., Lang, A. et al. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. Ann Hematol 93, 459–462 (2014). https://doi.org/10.1007/s00277-014-2009-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-014-2009-0